Gestala, a pioneering Chinese life sciences company, has successfully raised approximately $84 million across two funding rounds within its first six months of operation. This financial boost is aimed at developing an advanced ultrasound-based brain-computer interface (BCI) platform.
Initial Funding Rounds
The company officially launched on January 1, 2026, and promptly completed its Angel funding round, securing RMB150 million in March. Following this, Gestala raised an additional RMB420 million during its Angel+ round in July. This latest financial influx features contributions from notable investors, including HSG, Lens Technology, Sinovation Ventures, and C Capital. Existing backers such as Dalton Venture, Seas Capital, Tsing Song Capital, and Gobi Partners also participated in follow-on investments.
Visionary Leadership
Gestala was co-founded by Phoenix Peng and Tianqiao Chen, who is well-known for his role in establishing Shanda Group and the Tianqiao and Chrissy Chen Institute. Under their leadership, the company is dedicated to developing a non-invasive brain-computer interface leveraging ultrasound technology. Their long-term goal is to create a comprehensive platform capable of whole-brain “read and write” functionalities.
Innovative Approach
The company’s strategy integrates functional ultrasound imaging, focused ultrasound techniques, and artificial intelligence. Gestala is set to develop a multimodal brain foundation model that will explore the connections between neural activity, cerebral blood flow, medical imaging, and observable behaviors. This holistic approach positions Gestala at the forefront of neurotechnology.
Growing Team
To facilitate its ambitious projects, Gestala has recruited a team of 29 scientists and engineers, with plans to expand this number to around 45 by the end of 2026. The company’s headquarters in Chengdu oversees product development, engineering, manufacturing, and industrial translation. Meanwhile, its Shanghai office is dedicated to fundamental research, brain foundation models, clinical resources, and fostering scientific collaboration.
Global Expansion Plans
In addition to its current operations, Gestala plans to establish an international headquarters in either Singapore or Hong Kong, reflecting its commitment to global outreach and collaboration in the field of neurotechnology.
Target Applications
The immediate focus for Gestala is on chronic pain, with prospective applications extending to conditions such as depression, obsessive-compulsive disorder, and stroke rehabilitation. This diverse application range illustrates the potential impact of their technology on various neurological and psychiatric disorders.
Future Developments
Gestala anticipates unveiling its first-generation ultrasound BCI product and brain foundation model by the end of 2026. Following this, the company plans to initiate clinical trials and pursue medical device registration, marking a significant milestone in its development journey.
Conclusion
Gestala is at the cutting edge of brain-computer interface technology, merging various scientific disciplines to enhance our understanding of human intelligence. With substantial funding and a clear vision, the company is poised to make significant strides in the realm of neurotechnology, potentially transforming how we approach neurological conditions in the future.
- Gestala has raised $84 million in two funding rounds for its brain-computer interface development.
- The company aims to achieve non-invasive whole-brain functionalities using ultrasound technology.
- Initial applications focus on chronic pain, with future expansions into other neurological conditions.
- Gestala plans to grow its team and establish international headquarters for broader collaboration.
- The first-generation BCI product is expected to launch by the end of 2026.
Read more → pulse2.com